FMP
Replimune Group, Inc.
REPL
NASDAQ
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
10.14 USD
-0.22 (-2.17%)
2024
2023
2022
2021
0
0
0
0
2.65M
2.45M
4.58M
4.14M
-2.65M
-2.45M
-4.58M
-4.14M
234.77M
174.17M
115.14M
77.15M
174.96M
126.53M
79.55M
56.75M
59.81M
50.55M
38.77M
23.2M
0
0
0
0
0
0
0
23.2M
0
-5.68M
-1.06M
-665k
-234.77M
-177.08M
-118.31M
-79.95M
19.39M
3.08M
278k
-915k
-215.39M
-174M
-118.04M
-80.87M
408k
288k
1.16M
2.4M
-215.79M
-174.28M
-118.04M
-80.87M
-3.24
-2.99
-2.26
-1.75
-3.24
-2.99
-2.26
-1.75
66.57M
58.21M
52.21M
46.25M
66.57M
58.21M
52.21M
46.25M
-230.2M
-170.3M
-114.41M
-76.48M
2024
2023
2022
2021
-485.49M
-311.2M
-193.17M
-112.3M
-215.79M
-174.28M
-118.04M
-80.87M
0
0
0
0
0
0
0
0
-701.28M
-485.49M
-311.2M
-193.17M
-215.79M
-174.28M
-118.04M
-80.87M
2024
2023
2022
2021
52.35M
52.35M
55.58M
57.72M
2.65M
2.45M
4.58M
4.14M
-5.66M
-2.27M
-2.34M
-2.39M
55.36M
52.17M
53.34M
55.97M
2024
2023
2022
2021
0
0
0
0
0
0
0
0
0
0
0
0
All figures are in USD.